Supernus Pharmaceuticals, Inc. (SUPN)
USD 35.46
(-2.1%)
USD 35.46
(-2.1%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.4 Billion USD | -17.24% |
| 2022 | 1.7 Billion USD | 0.79% |
| 2021 | 1.68 Billion USD | 12.3% |
| 2020 | 1.5 Billion USD | 29.63% |
| 2019 | 1.16 Billion USD | 18.66% |
| 2018 | 977.81 Million USD | 130.36% |
| 2017 | 424.46 Million USD | 37.11% |
| 2016 | 309.56 Million USD | 64.03% |
| 2015 | 188.73 Million USD | 37.25% |
| 2014 | 137.5 Million USD | 23.89% |
| 2013 | 110.99 Million USD | 18.09% |
| 2012 | 93.98 Million USD | 74.93% |
| 2011 | 53.73 Million USD | 14.3% |
| 2010 | 47 Million USD | -41.16% |
| 2009 | 79.89 Million USD | 3.59% |
| 2008 | 77.13 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.3 Billion USD | -7.44% |
| 2024 Q3 | 1.34 Billion USD | 2.04% |
| 2024 Q2 | 1.31 Billion USD | 0.9% |
| 2023 FY | 1.4 Billion USD | -17.24% |
| 2023 Q1 | 1.79 Billion USD | 5.25% |
| 2023 Q3 | 1.28 Billion USD | -0.61% |
| 2023 Q2 | 1.29 Billion USD | -27.83% |
| 2023 Q4 | 1.4 Billion USD | 9.63% |
| 2022 Q3 | 1.69 Billion USD | -0.11% |
| 2022 FY | 1.7 Billion USD | 0.79% |
| 2022 Q1 | 1.63 Billion USD | -2.94% |
| 2022 Q2 | 1.69 Billion USD | 3.38% |
| 2022 Q4 | 1.7 Billion USD | 0.55% |
| 2021 FY | 1.68 Billion USD | 12.3% |
| 2021 Q3 | 1.55 Billion USD | -1.15% |
| 2021 Q2 | 1.57 Billion USD | 4.35% |
| 2021 Q1 | 1.5 Billion USD | 0.22% |
| 2021 Q4 | 1.68 Billion USD | 8.62% |
| 2020 Q3 | 1.51 Billion USD | 1.27% |
| 2020 FY | 1.5 Billion USD | 29.63% |
| 2020 Q1 | 1.18 Billion USD | 2.55% |
| 2020 Q2 | 1.49 Billion USD | 25.31% |
| 2020 Q4 | 1.5 Billion USD | -0.39% |
| 2019 Q2 | 1.06 Billion USD | 3.73% |
| 2019 Q1 | 1.02 Billion USD | 4.87% |
| 2019 Q3 | 1.1 Billion USD | 4.06% |
| 2019 FY | 1.16 Billion USD | 18.66% |
| 2019 Q4 | 1.16 Billion USD | 4.82% |
| 2018 Q4 | 977.81 Million USD | 5.99% |
| 2018 Q3 | 922.51 Million USD | 8.17% |
| 2018 FY | 977.81 Million USD | 130.36% |
| 2018 Q2 | 852.79 Million USD | 3.35% |
| 2018 Q1 | 825.16 Million USD | 94.4% |
| 2017 Q4 | 424.46 Million USD | 10.11% |
| 2017 Q3 | 385.47 Million USD | 11.29% |
| 2017 Q2 | 346.37 Million USD | 7.48% |
| 2017 Q1 | 322.25 Million USD | 4.1% |
| 2017 FY | 424.46 Million USD | 37.11% |
| 2016 FY | 309.56 Million USD | 64.03% |
| 2016 Q1 | 194.47 Million USD | 3.04% |
| 2016 Q3 | 285.11 Million USD | 30.41% |
| 2016 Q4 | 309.56 Million USD | 8.58% |
| 2016 Q2 | 218.63 Million USD | 12.42% |
| 2015 Q1 | 139.63 Million USD | 1.55% |
| 2015 FY | 188.73 Million USD | 37.25% |
| 2015 Q4 | 188.73 Million USD | 13.17% |
| 2015 Q3 | 166.77 Million USD | 8.17% |
| 2015 Q2 | 154.16 Million USD | 10.41% |
| 2014 Q1 | 97.52 Million USD | -12.14% |
| 2014 FY | 137.5 Million USD | 23.89% |
| 2014 Q4 | 137.5 Million USD | 8.85% |
| 2014 Q3 | 126.32 Million USD | 34.12% |
| 2014 Q2 | 94.19 Million USD | -3.41% |
| 2013 Q3 | 123.76 Million USD | -6.22% |
| 2013 Q4 | 110.99 Million USD | -10.32% |
| 2013 Q1 | 79.06 Million USD | -15.88% |
| 2013 FY | 110.99 Million USD | 18.09% |
| 2013 Q2 | 131.97 Million USD | 66.93% |
| 2012 Q2 | 79.96 Million USD | 85.1% |
| 2012 Q3 | 67.01 Million USD | -16.2% |
| 2012 Q4 | 93.98 Million USD | 40.25% |
| 2012 FY | 93.98 Million USD | 74.93% |
| 2012 Q1 | 43.2 Million USD | -19.59% |
| 2011 FY | 53.73 Million USD | 14.3% |
| 2011 Q3 | 32.3 Million USD | 0.0% |
| 2011 Q4 | 53.73 Million USD | 66.34% |
| 2010 FY | 47 Million USD | -41.16% |
| 2010 Q4 | 47 Million USD | -18.25% |
| 2010 Q3 | 57.5 Million USD | 0.0% |
| 2009 FY | 79.89 Million USD | 3.59% |
| 2009 Q4 | 79.89 Million USD | 0.0% |
| 2008 FY | 77.13 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Theratechnologies Inc. | 77.76 Million USD | -1711.746% |
| Harrow Health, Inc. | 311.75 Million USD | -351.95% |
| Dynavax Technologies Corporation | 997.09 Million USD | -41.308% |
| Biofrontera Inc. | 27.93 Million USD | -4944.311% |
| Cronos Group Inc. | 1.13 Billion USD | -24.221% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -9360.666% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -199.1% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -2418.324% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -6013.458% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -1622.97% |
| Radius Health, Inc. | 1.71 Billion USD | 17.889% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -2544.127% |
| DURECT Corporation | 45.18 Million USD | -3017.965% |
| ProPhase Labs, Inc. | 91.92 Million USD | -1432.713% |
| Safety Shot Inc | 12.7 Million USD | -10986.294% |
| Phibro Animal Health Corporation | 982.18 Million USD | -43.453% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -5992.332% |
| Alvotech | 950.09 Million USD | -48.299% |
| Assertio Holdings, Inc. | 286.41 Million USD | -391.929% |
| Rockwell Medical, Inc. | 52.17 Million USD | -2600.587% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -5052.225% |
| Procaps Group S.A. | 460.18 Million USD | -206.175% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | -93.462% |
| SCYNEXIS, Inc. | 128.41 Million USD | -997.232% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -1093.088% |
| Viatris Inc. | 47.68 Billion USD | 97.045% |
| OptiNose, Inc. | 107.72 Million USD | -1207.89% |
| SIGA Technologies, Inc. | 254.83 Million USD | -452.895% |
| Tilray Brands, Inc. | 4.33 Billion USD | 67.5% |
| PetIQ, Inc. | 868.22 Million USD | -62.282% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -5052.225% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 56.666% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -11722.085% |
| Alimera Sciences, Inc. | 153.52 Million USD | -817.757% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | -23.237% |
| Silver Spike Investment Corp. | 88.57 Million USD | -1490.694% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -23573.379% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -206.283% |
| Journey Medical Corporation | 76.84 Million USD | -1733.436% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -4069.09% |
| Alpha Teknova, Inc. | 128.58 Million USD | -995.738% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -4409.737% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -414.785% |
| PainReform Ltd. | 9.93 Million USD | -14089.094% |
| Cosmos Health Inc. | 66.29 Million USD | -2025.296% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -439.577% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -3153.312% |
| Embecta Corp. | 1.21 Billion USD | -16.022% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -16597.58% |
| Talphera, Inc. | 20.39 Million USD | -6808.443% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 10.506% |
| Incannex Healthcare Limited | 17.04 Million USD | -8165.249% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -10535.765% |
| Shineco, Inc. | 84.17 Million USD | -1573.779% |
| Procaps Group, S.A. | 460.18 Million USD | -206.175% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | -55.788% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -2353.894% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 14.667% |
| Alvotech | 950.09 Million USD | -48.299% |
| Hempacco Co., Inc. | 18.04 Million USD | -7708.961% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -246.902% |
| Bright Green Corporation | 17.4 Million USD | -7996.151% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -584.647% |
| Kamada Ltd. | 351.96 Million USD | -300.312% |
| Indivior PLC | 1.95 Billion USD | 27.791% |
| Evoke Pharma, Inc. | 7.06 Million USD | -19833.053% |
| Flora Growth Corp. | 23.62 Million USD | -5863.671% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -10535.765% |
| Evolus, Inc. | 188.99 Million USD | -645.498% |
| HUTCHMED (China) Limited | 1.27 Billion USD | -10.096% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 6.87% |
| Akanda Corp. | 8.83 Million USD | -15838.666% |